RxDoctor Payments Data

Theodore Hausler, DO

Family Medicine · Albany, NYNPI 1629413075

Payments from drug & device makers

$14,681in general payments, 2019–2025

Across 893 payments — averaging $16.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novo Nordisk$1K
  • GSK$1K
  • AstraZeneca$1K
  • Johnson & Johnson$698
  • Amgen$689
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$14,50299%
  • Education$1791%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)225$2,930
Novo Nordisk78$1,253
GSK70$1,239
AstraZeneca55$1,013
Johnson & Johnson42$698
Amgen(2 entities)43$689
Lilly USA, LLC40$689
Pfizer34$539
Boehringer Ingelheim23$523
Astellas Pharma US Inc20$479
Takeda Pharmaceuticals U.S.A., Inc.22$361
Bayer19$334
Exact Sciences15$301
Biohaven Pharmaceuticals, Inc.16$284
Novartis13$238
Merck13$190
Renalytix AI, Inc.9$184
Esperion Therapeutics, Inc.10$180
Galderma Laboratories, L.p.2$165
Biohaven Pharmaceutical Holding Company Ltd.13$141
Mannkind Corporation9$135
Currax Pharmaceuticals LLC9$134
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC7$130
Abbott8$125
Bausch Health US, LLC6$110
Amarin Pharma, Inc.7$109
Sanofi Pasteur Inc.7$102
Teva Pharmaceuticals USA, Inc.7$99
Axsome Therapeutics, Inc.6$98
Sanofi-aventis U.S. LLC4$95
E.r. Squibb & Sons, L.L.C.5$87
Ironshore Pharmaceuticals Inc.4$76
Nestle Healthcare Nutrition Inc.3$69
Idorsia Pharmaceuticals US Inc4$63
Daiichi Sankyo Inc.3$63
Lundbeck LLC2$59
Bioventus LLC2$53
Sunovion Pharmaceuticals Inc.3$50
Seqirus USA Inc2$42
Optinose US, Inc.2$40
Supernus Pharmaceuticals, Inc.2$40
Kowa Pharmaceuticals America, Inc.2$37
Collegium Pharmaceutical, Inc.2$34
Scilex Pharmaceuticals Inc.2$34
Incyte Corporation2$32
Therapeuticsmd, Inc.2$31
Ultragenyx Pharmaceutical Inc.2$31
Corcept Therapeutics2$31
Eisai Inc.1$24
Ascensia Diabetes Care US Inc.1$24
Neurocrine Biosciences, Inc.1$22
Endo Pharmaceuticals Inc.1$20
Phathom Pharmaceuticals, Inc.1$19
Ironwood Pharmaceuticals, Inc1$19
Bristol Myers Squibb1$17
IBSA Pharma Inc.1$16
Regeneron Healthcare Solutions, Inc.1$15
Sun Pharmaceutical Industries Inc.1$14
Biogen1$13
Aimmune Therapeutics, Inc.1$12

How this compares

$14,681 in reported general payments places this provider in the 95th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$35,822
Medicare patients
132
Services billed
463

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide44$70,125
OxycontinOxycodone Hcl25$43,000
FarxigaDapagliflozin Propanediol32$37,740
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$25,175
EliquisApixaban23$23,431
Janumet XrSitagliptin Phos/Metformin Hcl11$16,960
Breo ElliptaFluticasone/Vilanterol40$15,904
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr26$15,430
JanuviaSitagliptin Phosphate21$13,617
TradjentaLinagliptin24$12,284
JardianceEmpagliflozin12$12,243
Fentanyl17$4,524
Icosapent Ethyl21$4,270
SynthroidLevothyroxine Sodium28$2,447
Tamsulosin Hcl101$2,212

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,253$70,12544 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$1,239$56,509103 claims
AstraZenecaFarxiga$1,013$37,74032 claims
MerckJanumet Xr, Januvia$190$30,57632 claims
Boehringer IngelheimTradjenta, Jardiance$523$24,52836 claims
PfizerEliquis$539$23,43123 claims
AbbVieSynthroid$2,930$2,44728 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,321 family medicine providers in New York.

Other family medicine in Albany

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →